to keep it simple my focus isn't on *legal shorting* ..

Quote:

to keep it simple my focus isn't on *legal shorting* .. i've noted numerous times that the entity working the cycle of money (UP/DOWN) on IPIX had issues since their *imo* illegally orchestrated take up of December 2014 .. just shy of $5.00

I keep hearing this now and then but what was the evidence of a pump job back then? I look back and all I saw was an avalance of good news at the time:

Sep 2, 2014 Company focuses on meeting Nasdaq requirements
Oct 23, 2014 Positive Top-Line Brilacidin ABSSSI phase 2B results announced.
Nov 11, 2014 Announcement that B-OM Enrollement will start in December.
Nov 23, 2014 "Momentous December" PR
Dec 08, 2014 Brilacidin receives QIDP Designation
Dec 10, 2014 FDA Agrees that Prurisol phase 2 can begin.
Dec 22, 2014 Reports (Good) results of ITT Population in B ABSSSI phase 2B
Jan 05, 2015 Clinical success rates (Good) for B-ABSSSI
Jan 20, 2015 Spleen Lesion Disappears in Kevetrin patient

Granted I remember several positive articles, some from posters we know and love (Karin, Jim Bowie, etc.) but I wouldn't count them among an orchestrated pump. CTIX just dropped positive PR after positive PR with the winds at our back.

But then we lost the momentum, then Mako/Rosen beat the p*ss out of us, we failed to uplist as a result and funding through Aspire on the crappy OTC/OTCQB exchanges have ravaged us and left us unreachable by any institutional buyers. In addition to that we were marred by trial issues:

B ABSSSI phase 3 - not started due to lack of funding.
Kevetrin phase 1 - took way longer than expected.
B-OM Phase 2 - took way longer than expected. Appeared to have a relatively weak finish compared to the amazing interim which confused investors.
Prurisol phase 2 - possibly undershot the dosing and required a phase 2b to get proper valuation.
Prurisol phase 2b - Justified or not, skipping the interim look does not provide warm and fuzzy feelings. Here we sit going into 2H 2018 still wondering how well Prurisol works.
Kevetrin phase 2 AML@UoB - Combo trial funding disappeared on us.
Kevetrin phase 2a - Showed p53 modulation in humans but we didn't get a "It cures cancer!" PR like last time.

Even B-UP phase 2 results, an undeniable shining star of 2016/2017, could not help us shake the gloom. When you look at the string of PRs from late 2014/Jan 2015 compared to what has been done since then it's easy to see how we fell from the grace of the markets.

At $75M we still have more in our pipeline than we did when we were at $500M. Eventually the insanity will end and we will get our proper (higher) valuation. First the deal, then the uplist, then the 'tutes come buying. Leo's comin with the good news. Just hang in there.

Go IPIX!